Stereotactic radioablation for ventricular tachycardia
- 26.11.2021
- Schwerpunkt
Erschienen in:
- Verfasst von
- Stephan Hohmann, MD
- Henrike A. K. Hillmann, MD
- Johanna Müller-Leisse, MD MSc
- Jörg Eiringhaus, MD
- Christos Zormpas, MD
- Roland Merten, MD
- Christian Veltmann, MD
- David Duncker, MD
- Erschienen in
- Herzschrittmachertherapie + Elektrophysiologie | Ausgabe 1/2022
Abstract
Non-invasive stereotactic radioablation of ventricular tachycardia (VT) substrate has been proposed as a novel treatment modality for patients not eligible for catheter-based ablation or in whom this approach has failed. Initial clinical results are promising with good short-term efficacy in VT suppression and tolerable side effects. This article reviews the current clinical evidence for cardiac radioablation and gives an overview of important preclinical and translational results. Practical guidance is provided, and a cardiac radioablation planning and treatment workflow based on expert consensus and the authorsʼ institutional experience is set out.
Anzeige
- Titel
- Stereotactic radioablation for ventricular tachycardia
- Verfasst von
-
Stephan Hohmann, MD
Henrike A. K. Hillmann, MD
Johanna Müller-Leisse, MD MSc
Jörg Eiringhaus, MD
Christos Zormpas, MD
Roland Merten, MD
Christian Veltmann, MD
David Duncker, MD
- Publikationsdatum
- 26.11.2021
- Verlag
- Springer Medizin
- Erschienen in
-
Herzschrittmachertherapie + Elektrophysiologie / Ausgabe 1/2022
Print ISSN: 0938-7412
Elektronische ISSN: 1435-1544 - DOI
- https://doi.org/10.1007/s00399-021-00830-y
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
